Hosted on MSN11mon
Immuneering doses first subject in Phase I/IIa solid tumour trialpathway, IMM-6-415, will be evaluated as an oral, twice-daily treatment. Patients with rapidly accelerated fibrosarcoma (RAF), kirsten rat sarcoma (KRAS), neuroblastoma RAS (NRAS), or Harvey RAS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback